ScholarIQanswers from OpenAlex & ORCID
Xingsheng Hu
ResearcherPublications, citations & collaboration network
Xingsheng Hu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Xingsheng Hu have?
ScholarIQindexed works
Xingsheng Hu has 164 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Xingsheng Hu have?
ScholarIQcitation count
Xingsheng Hu has 1,838 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Xingsheng Hu?
ScholarIQh-index
Xingsheng Hu has an h-index of 23 in OpenAlex.
What is the i10-index of Xingsheng Hu?
ScholarIQi10-index
Xingsheng Hu has an i10-index of 50 in OpenAlex.
What is the ORCID of Xingsheng Hu?
ScholarIQorcid
The ORCID for Xingsheng Hu is on the source record.
What is the OpenAlex record for Xingsheng Hu?
ScholarIQopenalex
The OpenAlex for Xingsheng Hu is on the source record.
What are the most-cited papers on Xingsheng Hu?
ScholarIQmost cited works
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
Yuankai Shi, Xingsheng Hu, Shucai Zhang, Dongqing Lv, Lin Wu, Qitao Yu, Yiping Zhang, Li Liu, Xiang Wang, Ying Cheng, Zhiyong Ma, Hongrui Niu, Dong Wang, Jifeng Feng, Cheng Huang, Chunling Liu, Hui Zhao, Jingzhang Li, Xiaodong Zhang, Yong Jiang, Chuan Gu
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, Jifeng Feng, Zhiyong Ma, Jianying Zhou, Nong Yang, Lin Wu, Wangjun Liao, Dafang Zhong, Xiaohong Han, Ziping Wang, Xiaodong Zhang, Shukui Qin, Kejing Ying, Jian Feng, Jian Fang, Li Liu, Yong Jiang
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Hui Xia, Xingyang Xue, Huaxin Ding, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Xingsheng Hu, Sai‐Hong Ignatius Ou
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Shun Lü, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
Chaoyuan Liu, Wei Zhao, Junpeng Xie, Huashan Lin, Xingsheng Hu, Chang Li, Youlan Shang, Yapeng Wang, Yingjia Jiang, Meng-Ge Ding, Muyun Peng, Tian Xu, Ao’ran Hu, Yuda Huang, Yuan Gao, Xianling Liu, Jun Liu, Fang Ma